AIM ImmunoTech (AIM) Stock Runs On Coronavirus News

AIM ImmunoTech AIM Stock News

AIM ImmunoTech Inc (NYSEAMERICAN: AIM) is having a strong start to the trading session this morning, up more than 30% this morning. The gains come after the company announced that it’s getting involved in the fight against coronavirus. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

AIM Stock Flies After Announcing Coronavirus News

In a press release issued early this morning, AIM ImmunoTech said that it filed three provisional patent applications surrounding Ampligen. The company is working to use the treatment as a potential option in the fight against the Wuhan coronavirus.

In the release, AIM said that it believes that Ampligen has the potential to be both an early-onset treatment and prophylaxis against the Wuhan coronavirus. As such, the company quickly filed patents protecting its IP in the space. The patents are titled the following:

  1. Ampligen as a therapy for the Wuhan coronavirus;
  2. Ampligen as part of a proposed intranasal universal coronavirus vaccine that combines Ampligen with inactivated Wuhan coronavirus, conveying immunity and cross- protection and;
  3. a high-volume manufacturing process for Ampligen.

In a statement, Tom Equels, CEO at AIM, had the following to offer:

Our analysis of the RNA sequences of the SARS virus and the Wuhan coronavirus and our research lead AIM to believe Ampligen has significant therapeutic potential as both an early-onset treatment and prophylaxis against this new and deadly virus.

If clinical trials follow the results of SARS animal testing, this means helping people who are already sick as well as a prophylaxis for people directly exposed to the virus as it spreads, which is especially important for the medical professionals in hospital-like settings working to contain the global emergency, and those people quarantined in camps and on cruise ships.

AIM’s universal coronavirus vaccine concept is primarily meant to inoculate against the Wuhan coronavirus, but, through Ampligen’s unique capabilities, could also protect against other forms of coronavirus and future mutations of the Wuhan coronavirus. AIM is a small immunological research company, but we want to do our part. We believe humanity must stand together to defeat such viral threats. This is our effort to make a difference in this worldwide threat posed by the Wuhan coronavirus.

AIM Has Several Competitive Advantages

This is great news for AIM ImmunoTech and its investors as the company has several competitive advantages. First and foremost, as mentioned in the press release, the company recently produced more than 10,000 viles of Ampligen. This means that if the treatment is approved as a potential option to fight the Wuhan coronavirus, the company already has a large supply ready to be shipped. AIM also said in the press release that it is in a strong position to ship treatment to patients in areas hit by the Wuhan coronavirus.

It’s also important to keep in mind that Ampligen was studied in animals as a potential option to treat patients with SARS-coronavirus. The animal study did incredibly well, generating a 100% survival rate, compared to a 100% mortality rate in untreated animals.

Importantly, the SARS virus is very similar in key RNA sequences to the Wuhan coronavirus. As such, the company’s work against SARS, gives it a leg up when fighting against the Wuhan coronavirus.

Moreover, we’ve seen several press releases surrounding the development of a Wuhan coronavirus vaccine. However, we haven’t seen much when it comes to a treatment for those who have already contracted the virus. To my knowledge, AIM is the first pubicly traded company to say that it is working on a treatment for the Wuhan coronavirus. Being the first kid on the block has its advantages.

All in all, there’s plenty of reason for AIM and its investors to be excited here.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.